anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: This scoping review informs a health economics perspective on the treatment of paediatric obesity. The results detail recently published research findings on the cost-effectiveness of paediatric obesity treatments and identify key characteristics of cost-effective interventions.
METHODS: A structured search was applied to six databases with no data restriction through March 2023: Medline, Embase, Cochrane CENTRAL, CINAHL, and PsycINFO. Studies that included a cost analysis of an individual level, weight management intervention (behavioural, pharmacotherapy, and surgical) in youth, with obesity, ages 2 to 21 years were eligible for inclusion.
RESULTS: Of the 4371 records identified in the initial search, 353 underwent full-text review, 39 studies met the pre-specified inclusion criteria. The majority were published after 2010 (n = 36/39, 92%) and applied to high-income countries (n = 39/39, 100%). Thirty-five of the studies assessed the cost-effectiveness of lifestyle interventions (90%), and four studies assessed surgical outcomes (10%). No pharmacotherapy studies met eligibility criteria. Although the outcome measures differed across the studies, all four surgical interventions were reported to be cost-effective. Thirty of the 35 (85%) lifestyle modification studies were reported to be cost-effective compared to the study comparator examined.
CONCLUSIONS: There is a small amount of evidence that individual-level paediatric obesity treatment interventions are cost-effective and, in some cases cost-saving, with most of this work conducted on behavioural interventions. The economic evaluation of paediatric obesity interventions poses various methodologic challenges, which should be addressed in future research to fully use the potential of economic evaluation as an aid to decision-making.
PURPOSE:To obtain a preparation for central vein administration, containing glucose and amino acids. CONSTITUTION:A solution (the first solution) containing glucose is isolated from a solution (the second solution) containing amino acids. A desired amount of branched-chain amino acids (>=40wt.% branched-chain amino acids) is divided into suitable amounts of two portions and dissolved respectively in the glucose- containing solution (the first solution) and the amino acid-containing solution (the second solution). Both the solutions are mixed before use. In this preparation for central vein administration, branched-chain amino acids are contained in a high concentration of >=40wt.% and coloration due to decomposition of glucose can be prevented. This preparation has an improved shelf life.
NEW MATERIAL:A polyacetylene compound of formula I (R is -CH2OCOCH3 or formyl). EXAMPLE:2Z, 9Z-Pentadecadiene-4,6-diyne-1-yl acetate. USE:It is useful as a drug such as antiallergic, anti-inflammatory, or circulatory drug, because it has 5-lipoxygenase inhibitor and cyclooxygenase inhibitor activity. It can be orally given. PREPARATION:For example, crude drug, 'SAIKO', its original plant, MISHIMASAIKO (Bupleuram facatum L.) or a similar plant is extracted with a solvent such as hexane, and the solvent is distilled off. The remaining is fractionated by chromatography of cellulose column as a carrier using a solvent such as hexane as an eluent to collect the compound of the formula. In another process, a kind of polyacetylene is acetylated to give the subject compound.
PURPOSE:To obtain a soft film capsule mixed with alginic acid having excellent water resistance and heat resistance by crosslinking soft capsule covered with film comprising mixture of gelatin or lower methoxylpectine with specific amount of plasticizer and sodium alginate by positive ion. CONSTITUTION:100 pts.wt. gelatin or lower methoxylpectine is uniformly blended with 10-50 pts.wt. plasticizer such as glycerin or sorbitol and 0.3-10 pts.wt. sodium alginate, then made to dried or semi-dried film, thus a capsule is formed. Next, said film is crosslinked using at least divalent positive ion, especially preferably calcium ion to afford the aimed material. Resultant capsule is useful for fields such as food processing, physic, quasi-drug or cosmetics and easily preservable in distribution process having excellent stability of quality and excellent functionality. Further, the capsule is efficiently produced in shortened manufacturing process and reducing cost of equipment with excellent productivity.
1213494 Preventing agglomeration of powders DEUTSCHE GOLDUND SILBER SCHEIDEANSTALT 22 March 1968 [23 March 1967] 13931/68 Headings C5G and G10B [Also in Divisions A2 and F4] The agglomeration and reagglomeration of powdered materials is prevented by adding finely divided precipitated or pyrogenic hydrophobic silica to the materials either before or during their conversion to finely divided form. There may also be present finely divided, precipitated or pyrogenic hydrophilic silica. The hydrophobic silica may be pyrogenic SiO 2  with CH 3 - bonded to it, precipitated SiO 2  treated with organo silicon compounds, e.g. organohalogeno silanes or SiO 2  prepared by coprecipitation with water soluble organic compounds having reactive groups. There may be 0.1-20% of silica (overall) present and the ratio of hydrophobic to hydrophilic SiO 2  may be 1:10 to 1:1. The powdered material may be sulphur, MgO or chromium phosphate.
PIA BLOCK For subjects randomized to PAI , LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
The present invention relates to mammalian staufen, a double-stranded RNA-binding protein involved in mRNA transport and localization. The invention further relates to the demonstration of the association of a RNA-binding protein with the rough endoplasmic reticulum (RER), implicating staufen and related proteins in the transport of RNA to its site of translation. Broadly, the invention therefore relates to transport and translation of RNA. More specifically, the present invention relates to human and mouse staufen proteins and to the modulation of transport of RNA to the RER by these proteins. The present invention also relates to isolated nucleic acid molecules encoding mammalian staufen, as well as vectors and host cells harboring same. In addition, the present invention relates to screening assays for identifying modulators of staufen activity and to the identification of mutants thereof which abrogate their interaction with RER. Furthermore, the present invention relates to the use of the double-stranded RNA binding activity of staufen as a means to target proteins into virions. The invention in addition relates to the incorporation of staufen into RNA viruses and the use of overexpression of staufen to significantly decrease the infectivity thereof. More particularly, the present invention relates to a novel and broad class of molecules which can be used as carriers to target molecules into virions of RNA viruses and to decrease infectivity of a wide variety of RNA viruses including retroviruses.
The control group will receive routine care. This group will wear smart band for pulse rate, sleep, blood pressure, and SpO2 record for data collection times.
The early luteal phase after IVF treatment is only scarcely studied. During IVF treatment the early luteinizing hormone (LH) activity deficit induced after ovarian stimulation with exogenous gonadotropins will be partly covered by the bolus of hCG used for triggering of final oocyte maturation due to the long half-life of hCG. In addition, the luteal phase will be covered by exogenous progesterone supplementation. After successful implantation the embryo itself will provide the supportive LH activity, securing the function of the corpora lutea. However, during the early luteal phase and peri-implantation, recent data suggest that an early-mid-luteal hCG/LH deficiency exists after hCG trigger during which the corpus luteum lacks an optimal stimulation. Furthermore, the early luteal progesterone profile in IVF differs significantly from the progesterone profile of the natural cycle, in which the peak is reached around the time of implantation. With this non-invasive trial, we wish to further explore the early luteal phase profiles of progesterone, 17-Hydroxyprogesterone and hCG in order to optimize current luteal phase support policies in IVF and hopefully increase ongoing pregnancy rates.
Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
Preclinical mouse models are critical for understanding the pathophysiological response to infections and developing treatment strategies for sepsis. In keeping with ethical values, researchers follow guidelines to minimize the suffering of the mice. Weight loss is a criteria used as a humane end point, but there is no official recommendation for a maximum weight loss leading to euthanasia. To evaluate whether the thresholds used in daily practice are optimal, we performed a comprehensive retrospective analysis of data generated over 10 years with > 2300 mice used in models of infection with Listeria monocytogenes, Streptococcus pneumoniae, Candida albicans and H1N1 influenza virus. Weight loss segregated mice that survived from those that did not. Statistical analyses revealed that lowering the weight loss thresholds used (none, 30% or 20%) would have increased mortality rates due to the sacrifice of mice that survived infections (p < 0.01-0.001). Power calculations showed high variability and reduction of power as weight loss thresholds approached 20% for S. pneumoniae and L. monocytogenes models. Hence, weight loss thresholds need to be adapted to each model of infection used in a laboratory. Overall, weight loss is a valuable predictor of mortality that contributes to the robustness of composite scores. To our knowledge, this is the most extensive study exploring the relationship between weight loss threshold and sepsis outcome. It underscores the importance of the infection-model-specific evaluation of weight loss for use in clinical scores defining humane endpoints to minimize mouse suffering without compromising statistical power and scientific objectives.
Objective: Current clinician-rated tardive dyskinesia (TD) symptom scales have not addressed the expanding clinical signs and functional impact of TD. The study objective was to develop and test the reliability of a new integrated instrument. Methods: A movement disorder neurologist devised the outline of the rating scale. A Steering Committee (5 neurologists and 2 psychiatrists) provided revisions until consensus was reached. The Clinician's Tardive Inventory (CTI) assesses abnormal movements of the eye/eyelid/face, tongue/mouth, jaw, and limb/trunk; complex movements defined as complicated movements different from simple patterned movements or postures; and vocalizations. The CTI rates frequency of symptoms from 0 to 3 (ranging from absent to constant). Functional impairments, including activities of daily living (ADL), social impairment, symptom distress, and physical harm, are rated 0-3 (ranging from unawareness to severe impact). The CTI underwent interrater and test-retest reliability testing between February and June 2022 based on videos and accompanying vignettes, which were reviewed by 2 movement disorder specialists to determine adequacy. Four clinicians rated each video/vignette. Interrater agreement was analyzed via 2-way random-effects intraclass correlation (ICC), and test-retest agreement was assessed utilizing the Kendall tau-b. Results: Forty-five video/vignettes were assessed for interrater reliability and 16 for test-retest reliability. The most prevalent movements were those of the tongue and mouth (77.8%) and jaw (55.6%). ICCs for movement frequency for anatomic symptoms were as follows: anatomic symptom summary score 0.92, abnormal eye movement 0.89, abnormal tongue/mouth movement 0.91, abnormal jaw movement 0.89, abnormal limb movement 0.76, complex movement 0.87, and abnormal vocalization 0.77; ICCs for functional impairments were as follows: total impairment score 0.92, physical harm 0.82, social embarrassment 0.88, ADLs 0.83, and symptom bother 0.92; Retests were conducted a mean (SD) of 15 (3) days later with correlation coefficients ranging from 0.66 to 0.87. Conclusions: The CTI is a new integrated instrument with proven reliability in assessing TD signs and functional impacts. Future validation study is warranted.
O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
PURPOSE: To treat dermatosis such as psoriasis, virus- or ultraviolet irradiation- induced dermatosis and skin cancer by administration of a medicinal agent containing a compound having sesquiterpene structure. CONSTITUTION: Any kind of dermatosis is treated by administration of a medicinal composition containing a sesquiterpene-lactone having sesquiterpene structure, pref. having a bound peroxide (esp. pref. artemisinin or dihydroartemisinin). The medicinal composition is prepared into a form administrable parenterally, orally or locally by containing 0.01-35wt.% of the compound having sesquiterpene structure. The resulting preparation effectively treats various kinds of dermatosis, specifically, psoriasis, collagen-vascular disease, keratosis before getting malignant, Bowen's disease, malignant mole, basal cell cancer, squamous cell cancer, ultraviolet radiation-induced diseases including malignant melanoma, tumor, tubercle, viral tumor, blistering dermatosis, hermorrhoid, etc.
FIELD: medicine, immunology. SUBSTANCE: invention involves modifying a carrier with 0.3-0.4% of polyglucin solution. Sorbent is dried, activated with secondary sodium alkyl sulfate and activated sorbent is bound covalently with the protein ligand. By the first variant alumosilicate is used as a carrier and by the second variant - a mixture of magnetic powder and alumosilicate. Of protein ligands immunoglobulins against plague, cholera or tularemia pathogens can be used. Invention is used for production of immunosorbents for detection of specific reaction antigen-antibody. EFFECT: improved method of producing. 3 cl, 6 ex
Eligible patients with either Fanconi anemia (FA) or Dyskeratosis congenita (DC) will initially receive danazol at a dose of 5 mg/kg/d orally, rounded to the nearest 100 mg. For the first 8 weeks, the patient will be evaluated at weeks 2, 5, and 8 for hematologic response (HR). If the patient shows a hematological response (either a hemoglobin or platelet value no longer meeting blood cell count criteria for protocol inclusion in the absence of recent transfusions)within the first 12 weeks on the initial dose, the study drug will be continued at this dose for the next 6 weeks. If the patient fails to show any hematologic response within the first 12 weeks, the dose will be escalated to 10 mg/kg/day for the next 6 weeks, and an additional monitoring visit will be required at week 14. If at week 18, the patient fails to show any hematological response on the increased dose, the dose will be increased to 15 mg/kg/day for another 6 weeks (not to exceed 800 mg/day), and an additional monitoring visit will be required at week 20. At 24 weeks, if there is no response to this dose the patient will be taken off study drug and classified as a treatment failure, and will be monitored at weeks 38 and week 52). After week 24, if the patient continues to show a response, however, the study drug may be continued at the discretion of their primary care physician, with monitoring at weeks 38 and 52.

Should the patient lose the hematologic response on 5 or 10 mg/kg/day dosing at any point within the first 18 weeks of treatment, the dose will be escalated to 10 or 15 mg/kg/day (not to exceed 800 mg/day), respectively. The patient will continue to be evaluated at the next visit. If after week 24 no hematologic improvement is seen, the patient is then taken off study drug and monitored at weeks 38 and 52.
This invention provides compositions and methods for raising humoral antibody responses. The compositions are peptides containing major histocompatibility Class 11 antigen binding motifs (ABM) either native or inserted into the peptide sequence. The ABM can be at the carboxy or amino terminus of the peptide and is shown to provide a T cell epitope thereby assuring adequate T cell help. Associated with the ABM is an extended peptide that rests outside the Class 11 molecule and that is recognized by the B cell, a B cell epitope. This B cell epitope can be a contiguous peptide sequence either at the amino or carboxy terminus. The extended peptide can be irrelevant and can serve as a bridge to an attached B cell epitope such as a hapten. These haptens can be any chemical structure such as a fluorescein molecule or a carbohydrate. The compositions and methods of this invention provide inexpensive vaccines to raise antibodies.
BACKGROUND: Reducing current clinical symptoms and the risks of future exacerbations is the main goal of stable COPD management. Traditional Chinese medicine has unique advantages in chronic disease management. YuPingFeng (YPF), as a classical prescription, has been proven to reduce the risk of exacerbations, but there is a lack of high-quality evidence for the assessment of clinical symptoms and quality of life, particularly for the assessment of treatment response of microecology and immunity.
METHODS/DESIGN: This is a prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial. A total of 316 eligible subjects with moderate to severe COPD will be randomized 1:1 to receive YPF or placebo. Participants will receive either YPF or a placebo at 5 g three times daily for 52 weeks. The primary outcome will be the change in the COPD Assessment Test (CAT) score after 52 weeks of treatment. Secondary outcomes will include changes in the St George's Respiratory Questionnaire (SGRQ) score and clinical symptom score, among others. Outcomes will be measured at each visit. The study will continue for 52 weeks and will include six visits to each subject (at day 0 and weeks 4,12,24,36 and 52). In the event of exacerbations, subjects will be required to go back to the hospital once on the first day of exacerbation or when their condition permits.
DISCUSSION: This trial will provide research methods to evaluate the clinical efficacy, safety, and the possible mechanism of YPF in the treatment of stable moderate-to-severe COPD patients. In addition, we hope to provide more possibilities for TCM to participate in the management of stable COPD.
TRIAL REGISTRATION: The trial was registered at the Chinese Clinical Trials Registry on 3 June 2022 (ChiCTR2200060476; date recorded: 3/6/2022, https://www.chictr.org.cn/ ).
Children with cochlear implants (CI) communicate in noisy environments, such as in classrooms, where multiple talkers and reverberation are present. Speakers compensate for noise via the 'Lombard effect'. The present study examined the Lombard effect on the intensity and duration of stressed vowels in the speech of children with Cochlear Implants (CIs) as compared to children with Normal Hearing (NH), focusing on the effects of speech-shaped noise (SSN) and speech-shaped noise with reverberation (SSN+Reverberation). The sample consisted of 7 children with CIs and 7 children with NH, aged 7-12 years. Regarding intensity, a) children with CIs produced stressed vowels with an overall greater intensity across acoustic conditions as compared to NH peers, b) both groups increased their stressed vowel intensity for all vowels from Quiet to both noise conditions, and c) children with NH further increased their intensity when reverberation was added to SSN, esp. for the vowel /u/. Regarding duration, longer stressed vowels were produced by children with CIs as compared to NH in Quiet and SSN conditions but the effect was retained only for the vowels /i/, /o/ and /u/ when reverberation was added to noise. The SSN+Reverberation condition induced systematic lengthening in stressed vowels for children with NH. Furthermore, although greater intensity and duration ratios of stressed/unstressed syllables were observed for children with NH as compared to CIs in Quiet condition, they diminished with noise. The differences observed across groups have implications for speaking in classroom noise.
Background: This study investigated the association of four metabolic obesity phenotypes with incident coronary artery disease and stroke in a large-scale, community population-based, prospective Korean cohort observed for over 10 years. Methods: The study participants included 7374 adults aged 40-69 years, drawn from the Korean Genome and Epidemiology Study. Participants with different metabolic obesity phenotypes were categorized according to body weight and metabolic health status into four groups: metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy nonobese (MUHNO), and metabolically unhealthy obese (MUHO). Combined cardiovascular events were defined as coronary artery disease and stroke. We used multivariate Cox proportional hazards regression models to prospectively assess hazard ratios (HRs) with 95% confidence intervals (CIs) for incident coronary artery disease or stroke over 10 years after the baseline survey. Results: During the follow-up period, newly developed coronary artery disease, stroke, and combined cardiovascular events were diagnosed in 151 (2.0%), 137 (1.9%), and 283 (3.8%) participants, respectively. After adjusting for confounding variables, the HRs (95% CIs) for incident combined cardiovascular events were 1.81 (1.34-2.46) in the MUHO group, 1.29 (0.92-1.81) in the MUHNO group, and 1.21 (0.81-1.79) in the MHO group compared with those in the MHNO group. Conclusions: This study revealed distinct risks associated with four metabolic obesity phenotypes concerning incident coronary artery disease and stroke. After adjusting for potential confounding variables, the results indicated that MUHO, but not MUHNO or MHO, showed a higher risk of developing coronary artery disease and stroke than MHNO.
Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).